NOT-DK-20-018: Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK

In order to rapidly improve our understanding and available control measures for COVID-19, NIDDK is encouraging the submission of applications for Competitive Revisions to active grants to address the following research areas of interest:

Microsoft AI for Health

This grant program provides Azure cloud and High-Performance Computing capabilities. Our team of AI for Health data science experts, whose mission is to improve the health of people and communities worldwide, is also open to collaborations with COVID-19 researchers as they tackle this critical challenge. More broadly, Microsoft’s research scientists across the world, spanning computer science, biology, medicine, and public health, will also be available to provide advice and collaborate per mutual interest.

NOT-DC-20-004: Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19)

National Institute on Deafness and Other Communication Disorders (NIDCD) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in relation to NIDCD’s scientific mission areas of hearing, balance, taste, smell, voice, speech and language.

NOT-CA-20-042: Notice of Special Interest (NOSI): National Cancer Institute Announcement Regarding Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 (COVID-19)

The National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and the effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), on cancer, and vice versa.

NOT-CA-20-043: Notice of Special Interest (NOSI): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19)

The NCI Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs encourage applications from small businesses with NCI-funded active NCI SBIR/STTR awards that have a strong potential to be adapted/repurposed for use as a prophylactic, therapeutic or diagnostic tool for SARS-CoV-2 (COVID-19) in cancer patients, cancer survivors, and in the general population. A compelling rationale should be presented and linked to an appropriate research plan to generate data in support of the new proposed use. Areas of interest include but not limited to:

NOT-AT-20-011: Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 (COVID-19)

NCCIH, NIA, and NIAAA are issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). Topics of specific interest for this NOSI include research on stress management strategies, including mind and body approaches, that individuals may engage in remotely to address stressors related to social distancing, as well as to address recovery and recurrence of symptoms during and after COVID-19 infections.

NEA CARES Act Grants

You must submit to Grants.gov by 04/22/2020 with full proposal due 05/04/2020. The Coronavirus Aid, Relief, and Economic Security (CARES) Act recognizes that the nonprofit arts industry is an important sector of America’s economy. The National Endowment for the Arts will award funds to nonprofit arts organizations across the country to help these entities and their employees endure the economic hardships caused by the forced closure of their operations due to the spread of COVID-19.

Providing Enhanced Medical Support for Patients with Primary Immunodeficiency Disorders

Pfizer is offering grants through a program entitled Providing Enhanced Medical Support for Patients with Primary Immunodeficiency Disorders. Individual projects of up to $250,000 will be considered for projects that leverage the utilization of innovative technology platforms for distant learning to reach the intended audience with a focus on patient outreach, medical support and telework. IHEs and health providers are eligible to apply. 

Merck KGaA Research Grants

Merck KGaA is offering research grants to stimulate innovative research in challenging areas of future importance. Grants of 100,000 to 500,000 euro (approximately $110,000 to $550,000) for up to three years are available for the focus area of pandemic preparedness and fighting new emerging viral infectious diseases. This opportunity is open to U.S.-based researchers.